JPS6361929B2 - - Google Patents
Info
- Publication number
- JPS6361929B2 JPS6361929B2 JP55162621A JP16262180A JPS6361929B2 JP S6361929 B2 JPS6361929 B2 JP S6361929B2 JP 55162621 A JP55162621 A JP 55162621A JP 16262180 A JP16262180 A JP 16262180A JP S6361929 B2 JPS6361929 B2 JP S6361929B2
- Authority
- JP
- Japan
- Prior art keywords
- ascofuranone
- mice
- days
- administered
- intraperitoneally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- VGYPZLGWVQQOST-UHFFFAOYSA-N Ascofuranone Natural products OC=1C(Cl)=C(C)C(C=O)=C(O)C=1CC=C(C)CCC=C(C)C1CC(=O)C(C)(C)O1 VGYPZLGWVQQOST-UHFFFAOYSA-N 0.000 claims description 44
- VGYPZLGWVQQOST-JUERRSSISA-N ascofuranone Chemical compound OC=1C(Cl)=C(C)C(C=O)=C(O)C=1C\C=C(/C)CC\C=C(/C)[C@@H]1CC(=O)C(C)(C)O1 VGYPZLGWVQQOST-JUERRSSISA-N 0.000 claims description 44
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 description 32
- 206010028980 Neoplasm Diseases 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000002054 transplantation Methods 0.000 description 9
- 208000032839 leukemia Diseases 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 229920001615 Tragacanth Polymers 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 229920000053 polysorbate 80 Polymers 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 241000416162 Astragalus gummifer Species 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960001438 immunostimulant agent Drugs 0.000 description 4
- 239000003022 immunostimulating agent Substances 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000001668 nucleic acid synthesis Methods 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 206010065588 Thymus enlargement Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000305 astragalus gummifer gum Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Landscapes
- Furan Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP55162621A JPS5788119A (en) | 1980-11-20 | 1980-11-20 | Antitumor agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP55162621A JPS5788119A (en) | 1980-11-20 | 1980-11-20 | Antitumor agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5788119A JPS5788119A (en) | 1982-06-01 |
| JPS6361929B2 true JPS6361929B2 (fr) | 1988-11-30 |
Family
ID=15758082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP55162621A Granted JPS5788119A (en) | 1980-11-20 | 1980-11-20 | Antitumor agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5788119A (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005112755A (ja) * | 2003-10-06 | 2005-04-28 | Arigen Inc | フェノール系誘導体を有効成分とするクリプトスポリジウム症の予防・治療剤 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240129695A (ko) * | 2023-02-21 | 2024-08-28 | 대구가톨릭대학교산학협력단 | 아스코푸라논을 유효성분으로 포함하는 암 치료용 약학적 조성물 |
-
1980
- 1980-11-20 JP JP55162621A patent/JPS5788119A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005112755A (ja) * | 2003-10-06 | 2005-04-28 | Arigen Inc | フェノール系誘導体を有効成分とするクリプトスポリジウム症の予防・治療剤 |
| JP4553569B2 (ja) * | 2003-10-06 | 2010-09-29 | アリジェン製薬株式会社 | フェノール系誘導体を有効成分とするクリプトスポリジウム症の予防・治療剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5788119A (en) | 1982-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USRE40862E1 (en) | Gossypolone for the treatment of cancer | |
| US5225404A (en) | Methods of treating colon tumors with tumor-inhibiting camptothecin compounds | |
| RU2153332C2 (ru) | Способ сенсибилизации раковых клеток к лизису, опосредованному клетками-киллерами | |
| Bliznakov | Effect of stimulation of the host defense system by coenzyme Q10 on dibenzpyrene-induced tumors and infection with Friend leukemia virus in mice | |
| AU619022B2 (en) | Pharmaceutical compositions for the inhibition of tumor metastasis | |
| JPS62228026A (ja) | 免疫増強剤 | |
| JP2847783B2 (ja) | 抗癌活性増強剤 | |
| US6255291B1 (en) | Composition and method for treating cancer and immunological disorders resulting in chronic conditions | |
| CN112022871A (zh) | 金诺芬在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| KR950008767B1 (ko) | 에브셀렌(Ebselen)의 새로운 의약적 용도 | |
| Youn et al. | Inhibition of C3H/He mouse mammary tumor growth by combined treatment with cyclophosphamide and polyadenylic-polyuridylic acid | |
| JPH07501534A (ja) | ガンの治療のためのクレアチンホスフェート又はホスホエノールピルビン酸の使用 | |
| Gottschalk et al. | The action of cortisone and ACTH on transplanted mouse tumors | |
| JPS6361929B2 (fr) | ||
| US5763419A (en) | Treatment of malignant tumors with 8-chloroadenosine 3',5'-cyclic monophasphate | |
| JPH0686377B2 (ja) | がん転移抑制剤 | |
| Algarra et al. | Generation and control of metastasis in experimental tumor systems; inhibition of experimental metastases by a tilorone analogue | |
| KR20210039414A (ko) | 암의 치료를 위한 병용 요법 | |
| Gresser et al. | Effectiveness of Mouse Interferon α/β Compared to Single-Agent Chemotherapy in Increasing Survival Time of Mice After Intravenous Inoculation of Friend Erythroleukemial Cells | |
| NL8401226A (nl) | Farmaceutisch produkt met anti-tumorwerking; gebruik van een farmaceutisch produkt of van farmaceutische samenstellingen in een anti-tumortherapie. | |
| RU2782931C2 (ru) | Производные индол-3-карбоновой кислоты, обладающие противоопухолевой активностью | |
| Crooks et al. | Use of L-canavanine as a chemotherapeutic agent for the treatment of pancreatic cancer | |
| RU2211035C1 (ru) | Противотуберкулезный препарат | |
| RU2034543C1 (ru) | Противоопухолевое средство | |
| JPH04182427A (ja) | キサントシリンｘジメチルエーテルを含有する抗腫瘍剤 |